Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2, Double-Blind, Placebo-Controlled, Dose Escalation and Expansion Study of ALVR106 in Addition to Standard of Care for the Treatment of High-Risk Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant

NCT04933968 is registered in ClinicalTrials.gov with AlloVir as lead sponsor.

NCT NCT04933968
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04933968 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2, Double-Blind, Placebo-Controlled, Dose Escalation and Expansion Study of ALVR106 in Addition to Standard of Care for the Treatment of High-Risk Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant
Lead sponsor
AlloVir
Phase
Phase 1/2
Overall status
Terminated
Start date
March 21, 2022
Completion date
January 31, 2024
Enrollment
17 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

human metapneumovirus (hmpv) infection, influenza infection, parainfluenza (piv) infection, respiratory syncytial viral (rsv) infection, respiratory tract viral infections